- R D-Driven and AI-Powered Biopharmaceutical Company | Sanofi
Sanofi is a research development-driven, AI-powered healthcare biopharmaceutical company committed to improving lives through innovative medicines vaccines
- Sanofi Pharmaceuticals - Healthcare Innovations | Sanofi USA
Discover how Sanofi, a global pharmaceutical company, is shaping healthcare in the US with innovative solutions and treatments
- Sanofi - Wikipedia
Sanofi engages in the research and development, manufacturing, and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications
- Sanofi signs 2nd biotech deal of the day - fiercebiotech. com
Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody therapy designed to treat Alzheimer's disease | Sanofi is back with
- Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine . . .
The acquisition augments Sanofi's presence in adult immunization by bringing together Dynavax's vaccines with Sanofi's global scale, development capabilities and commercial reach
- Sanofi MS Drug Takes Double Hit With FDA, Trial Setbacks
Sanofi’s experimental multiple sclerosis drug got hit with two setbacks on Monday: a regulatory delay in the US as well as a failure in a late-stage clinical trial
- Our Company - Sanofi U. S.
Learn about Sanofi, a leading global pharmaceutical company in the US, advancing specialty care, vaccines, and consumer healthcare
- Sanofi MS drug hits two setbacks | BioPharma Dive
Sanofi MS drug hits two setbacks Tolebrutinib failed a Phase 3 study in “primary progressive” multiple sclerosis and is facing a delayed U S approval decision in another form of the disease
|